PMID- 22059997
OWN - NLM
STAT- MEDLINE
DCOM- 20120109
LR  - 20211021
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 166
IP  - 3
DP  - 2011 Dec
TI  - The effect of azithromycin on the maturation and function of murine bone 
      marrow-derived dendritic cells.
PG  - 385-92
LID - 10.1111/j.1365-2249.2011.04480.x [doi]
AB  - Dendritic cells (DCs) are professional antigen-presenting cells capable of 
      initiating primary/adaptive immune responses and tolerance. DC functions are 
      regulated by their state of maturation. However, the molecular pathways leading 
      to DC development and maturation remain poorly understood. We attempted to 
      determine whether inhibition of nuclear factor kappa B (NF-kappaB), which is one of 
      the pivotal pathways underlying these processes, could induce immunophenotypic 
      and functional changes in lipopolysaccharide-induced mature DCs derived from 
      murine bone marrow. A comparative in vitro study of five clinically used drugs 
      that are known to inhibit NF-kappaB demonstrated that azithromycin, a macrolide 
      antibiotic, significantly inhibited expression of co-stimulatory molecules (CD40 
      and CD86) and major histocompatibility complex (MHC) class II by DCs. It also 
      reduced Toll-like receptor 4 expression, interleukin-12 production and the 
      allostimulatory capacity of DCs. These data suggest that azithromycin, as not 
      only an NF-kappaB inhibitor but also an antibiotic, has potential as a novel drug for 
      manipulation of allogeneic responses.
CI  - (c) 2011 The Authors. Clinical and Experimental Immunology (c) 2011 British Society 
      for Immunology.
FAU - Iwamoto, S
AU  - Iwamoto S
AD  - Department of Pediatrics and Cell Transplantation, Mie University Graduate School 
      of Medicine, Tsu, Mie, Japan.
FAU - Kumamoto, T
AU  - Kumamoto T
FAU - Azuma, E
AU  - Azuma E
FAU - Hirayama, M
AU  - Hirayama M
FAU - Ito, M
AU  - Ito M
FAU - Amano, K
AU  - Amano K
FAU - Ido, M
AU  - Ido M
FAU - Komada, Y
AU  - Komada Y
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (B7-2 Antigen)
RN  - 0 (CD40 Antigens)
RN  - 0 (Cytokines)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NF-kappa B)
RN  - 0 (Toll-Like Receptor 4)
RN  - 187348-17-0 (Interleukin-12)
RN  - 1C6V77QF41 (Cholecalciferol)
RN  - 83905-01-5 (Azithromycin)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - Animals
MH  - Azithromycin/*pharmacology
MH  - B7-2 Antigen/metabolism
MH  - Bone Marrow Cells/drug effects
MH  - CD40 Antigens/metabolism
MH  - Cholecalciferol/pharmacology
MH  - Clarithromycin/pharmacology
MH  - Cytokines/metabolism
MH  - Dendritic Cells/*drug effects/*immunology/metabolism
MH  - Female
MH  - Interleukin-12/biosynthesis
MH  - Lipopolysaccharides/immunology
MH  - Lymphocyte Culture Test, Mixed
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - NF-kappa B/antagonists & inhibitors/immunology
MH  - Toll-Like Receptor 4/immunology
PMC - PMC3232387
EDAT- 2011/11/09 06:00
MHDA- 2012/01/10 06:00
PMCR- 2012/12/01
CRDT- 2011/11/09 06:00
PHST- 2011/11/09 06:00 [entrez]
PHST- 2011/11/09 06:00 [pubmed]
PHST- 2012/01/10 06:00 [medline]
PHST- 2012/12/01 00:00 [pmc-release]
AID - 10.1111/j.1365-2249.2011.04480.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2011 Dec;166(3):385-92. doi: 10.1111/j.1365-2249.2011.04480.x.